The EU Commission presents the pharmaceutical strategy for Europe

On 25 November 2020, the European Commission (the Commission) unveiled its Pharmaceutical Strategy for Europe (PSE), a wide-ranging document that discusses a series of broad policy statements, tentative considerations and concrete measures to tackle the many challenges faced by the pharmaceutical sector and its diverse stakeholders (see, attached Commission Communication (2020) 761 final; Commission press release; and Commission Q&A). The announcement follows an extensive period of consultation, study and preparation (see, Van Bael & Bellis Life Sciences News Alerts of 20 October 2020; 12 August 2020; 17 June 2020; 3 June 2020; and 28 May 2020). According to the Commission, the PSE is built on four pillars, each of which covers a large terrain of its own. 1. Ensuring patients

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)

Quotation

Peter L'Ecluse, Catherine Longeval, Koen T'Syen, The EU Commission presents the pharmaceutical strategy for Europe, 25 November 2020, e-Competitions November 2020, Art. N° 98056

Visites 221

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues